Your Messages Inbox
Your Article Summary
See Latest ArticlesAfinitor approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib
Novartis, 03/31/09
Novartis announced that Afinitor tablets has been approved by the US Food and Drug Administration for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent or Nexavar (sorafenib). Prior to Afinitor, no other therapy has been studied in a Phase III trial in this patient population where there is an important unmet medical need. Sutent and Nexavar are commonly used as initial treatments for advanced RCC.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD
Novartis, 12/04/09
Safety concerns slow new drug review and approval processes
Formulary , 12/02/09
Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia
Teva Pharmaceutical Industries, 12/02/09
Article Search
Sponsor